Embedded Files
Synthetic Biology Platform Developing Targeted Therapeutics
Human Fat/Lipids Absorption & Digestion
For decades researches and drug developers have been trying to find a solution for the western's world most growing epidemic: MASLD-MASH Metabolic dysfunction-associated steatohepatitis liver disease. Currently, MASLD is a clear unmet need, leaving 100 Million adults in the U.S alone with no treatment. If MASLD is left untreated, it can progress and become a very serious irreversible condition, that will require liver transplant or cause death.
Purpose Bio's scientific breakthrough is potentially the solution millions of patients around the globe have been waiting for.
Our Platform Technology is enabling the development of novel therapeutics for Cardiometabolic Diseases in the Metabolic Syndrome umbrella of diseases. Our first indications are MASLD-MASH, Hyperlipidemia and Obesity, with additional indications in discovery.
Our Platform is powered by AI algorithms, proprietary library of unique novel Enzymes, and synthetic biology engineering capabilities.
We engineer enzymes into oral and safe proprietary delivery mechanisms.
contact us: lital@purposebio.com
Page updated
Report abuse